Skip to main content

24.10.2017 | Systemic Therapies (M Liu and T Haddad, Section Editors) | Ausgabe 4/2017

Current Breast Cancer Reports 4/2017

Androgen Receptor-Targeted Therapy for Breast Cancer

Current Breast Cancer Reports > Ausgabe 4/2017
Tomas G. Lyons, Tiffany A. Traina
Wichtige Hinweise
This article is part of the Topical Collection on Systemic Therapies


Purpose of Review

Emerging evidence has identified the androgen receptor (AR) pathway as a potential driver for breast cancer (BC) carcinogenesis. The prevalence of AR expression differs across breast cancer subtypes, and its prognostic role in BC is not clear. Triple-negative breast cancer (TNBC) is a heterogeneously diverse disease, which includes a subset that may be androgen driven. This review will discuss the role of AR across the differing subtypes of BC and summarize the most recent clinical trial data for the use of androgen-directed therapy in the treatment of AR+ breast cancer, with a particular emphasis on TNBC.

Recent Findings

Preclinical and clinical data support the activity of the anti-androgen bicalutamide and more recent, next-generation, AR-targeted agents such as enzalutamide in targeting the AR in TNBC. In addition, novel agents which reduce androgen production such as abiraterone acetate and seviteronel are now being tested in BC. As our understanding of the interplay between AR and signaling pathways involving ER and HER2 grows, dual pathway inhibition may prove to be beneficial through informative, combinatorial approaches such as AR antagonism with CDK4/6 pathway inhibitors or PI3K inhibitors.


Over the recent years, there is accumulating evidence that AR signaling is a relevant driver for some subsets of breast cancer. Several agents have now consistently demonstrated a signal of activity when targeting the androgen receptor in TNBC in particular. We need to better define which patients are most likely to benefit from an AR-directed approach. Ongoing and future trials aim to clarify the role of targeting AR with single agent and combinatorial therapies in both the metastatic and adjuvant setting. It is hoped that these trials, which incorporate informative correlative components, will further our understanding of the biology of AR+ BC and will show the way to an increased number of treatment options and improved outcomes for our patients.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2017

Current Breast Cancer Reports 4/2017 Zur Ausgabe

Breast Cancer Screening and Imaging (HTC Le-Petross and BE Adrada, Section Editors)

Axillary Nodal Staging with Contrast-Enhanced Ultrasound

Breast Cancer Screening and Imaging (HTC Le-Petross and BE Adrada, Section Editors)

How Effective Is Mammography as a Screening Tool?

Systemic Therapies (M Liu and T Haddad, Section Editors)

Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women

Systemic Therapies (M Liu and T Haddad, Section Editors)

Immunotherapy Approaches to Breast Cancer

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.